scholarly journals Utility siting of WECS: a preliminary legal/regulatory assessment

1981 ◽  
Author(s):  
R. Noun ◽  
M. Lotker ◽  
H. Friesema
Keyword(s):  
Regulatory Assessment

scholarly journals A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013–2016

2020 ◽  
Vol 54 (6) ◽  
pp. 1428-1435
Author(s):  
Prisha Patel ◽  
Daniela Marreco Cerqueira ◽  
Gustavo Mendes Lima Santos ◽  
Renata de Lima Soares ◽  
Varley Dias Sousa ◽  
...  
Keyword(s):  
Performance Improvement ◽  
Review Process ◽  
Response Times ◽  
Regulatory Agencies ◽  
Regulatory Review ◽  
Performance Targets ◽  
Approval Time ◽  
Timely Access ◽  
Data Points ◽  
Regulatory Assessment

Abstract Background The Brazilian health regulatory agency (Agência Nacional de Vigilância Sanitária, ANVISA) has embarked on transformational initiatives to fulfill its mandate to provide timely access to safe, effective, and quality therapeutics. A new Brazilian law was enacted to provide the agency with greater flexibility. Optimizing Efficiencies in Regulatory Agencies (OpERA) is a regulatory-strengthening program that seeks to provide benchmarking data that can be used to define performance targets and focus performance improvement. The objective of this study was to use OpERA methodology to undertake a retrospective analysis of the timelines associated with important components of the ANVISA regulatory review process to establish a baseline against which the influence of the new law could be measured. Methods The OpERA tool was used to collect specific milestone data that identify time periods, review stages, and data points for products approved by ANVISA 2013–2016. Results For the 138 products approved in this cohort, the overall median approval time was 795 days. ANVISA and submitting companies will need to reduce their review and response times by approximately half in order to meet the total time goal of 365 days. Conclusions The observations from this baseline study have identified opportunities for ANVISA and sponsor companies to collaborate to reduce regulatory assessment times while assuring the timely approval of safe and effective, quality medicines. These analyses will be repeated to determine how the provisions of the new Law will impact the activities of ANVISA and the extent of sponsors' contributions to this effort.

scholarly journals A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies

2016 ◽  
Vol 19 (6) ◽  
pp. 746-750 ◽  
Author(s):  
Martin Ho ◽  
Anindita Saha ◽  
K. Kimberly McCleary ◽  
Bennett Levitan ◽  
Stephanie Christopher ◽  
...  
Keyword(s):  
Patient Preferences ◽  
Medical Technologies ◽  
Regulatory Assessment

Regulatory assessment of the FLAVR SAVR tomato

1994 ◽  
Vol 5 (4) ◽  
pp. 105-110 ◽  
Author(s):  
Keith Redenbaugh ◽  
William Hiatt ◽  
Belinda Martineau ◽  
Donald Emlay
Keyword(s):  
Regulatory Assessment

Regulatory assessment of new drugs in developing countries

The Lancet ◽  
2003 ◽  
Vol 362 (9379) ◽  
pp. 249-250
Author(s):  
Chiara Pandolfini ◽  
Maurizio Bonati ◽  
Valerio Reggi ◽  
Albert Figueras
Keyword(s):  
Developing Countries ◽  
New Drugs ◽  
Regulatory Assessment
Sign in / Sign up

Export Citation Format

Share Document